Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904)

被引：0
|
作者：
Takayama, Koichi
Inoue, Koji
Takeshita, Masafumi
Tashiro, Naoki
Harada, Taishi
Seto, Takashi
Imanaga, Tomotoshi
Fujimoto, Noriko
Nakagaki, Noriaki
Kawasaki, Masayuki
Kishimoto, Junji
Ichinose, Yukito
机构：
[1] Kyushu Univ, Res Inst Dis Chest, Grad Sch Med Sci, Fukuoka 812, Japan
[2] Kitakyushu Municipal Med Ctr, Dept Resp Med, Kitakyushu, Fukuoka, Japan
[3] Fukuoka Univ, Sch Med, Dept Resp Med, Fukuoka 81401, Japan
[4] Kyushu Natl Canc Ctr, Dept Med Oncol, Fukuoka, Japan
[5] Steel Mem Yawata Hosp, Dept Resp Dis, Kitakyushu, Fukuoka, Japan
[6] St Marys Hosp, Dept Resp Dis, Kurume, Fukuoka, Japan
[7] Natl Hosp Org Fukuoka Higashi Med Ctr, Dept Resp Dis, Fukuoka, Japan
[8] Natl Hosp Org Omuta Hosp, Dept Resp Med, Omuta, Japan
[9] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 812, Japan
[10] Kyushu Natl Canc Ctr, Clin Res Inst, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8111
引用
收藏
页数：1
相关论文
共 50 条
  • [1] RANDOMIZED PHASE II STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN ADVANCED NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (LOGIK 0904)
    Shiraishi, Yoshimasa
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S403 - S404
  • [2] RANDOMIZED STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN NON-SQUAMOUS NSCLC (LOGIK0904)
    Moriwaki, Atsushi
    Inoue, Koji
    Takeshita, Masafumi
    Harada, Taishi
    Tashiro, Naoki
    Seto, Takashi
    Imanaga, Tomotoshi
    Fujimoto, Noriko
    Nakagaki, Noriaki
    Kawasaki, Masayuki
    Kishimoto, Junji
    Takayama, Koichi
    Ichinose, Yukito
    [J]. RESPIROLOGY, 2013, 18 : 27 - 27
  • [3] Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [5] Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab for Japanese nonsquamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Hayashi, Mina
    Shimizu, Toshiki
    Nomura, Shosaku
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Socinski, Mark A.
    Garon, Edward B.
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Hermann, Robert C.
    Jotte, Robert M.
    Beck, Thaddeus
    Richards, Donald A.
    Guba, Susan C.
    Liu, Jingyi
    Frimodt-Moller, Bente
    John, William J.
    Obasaju, Coleman K.
    Pennella, Eduardo J.
    Bonomi, Philip
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4349 - U77
  • [7] PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Zinner, Ralph G.
    Obasaju, Coleman K.
    Spigel, David R.
    Weaver, Robert W.
    Beck, J. Thaddeus
    Waterhouse, David M.
    Modiano, Manuel R.
    Hrinczenko, Borys
    Nikolinakos, Petros G.
    Liu, Jingyi
    Koustenis, Andrew G.
    Winfree, Katherine B.
    Melemed, Symantha A.
    Guba, Susan C.
    Ortuzar, Waldo I.
    Desaiah, Durisala
    Treat, Joseph A.
    Govindan, Ramaswamy
    Ross, Helen J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : 134 - 142
  • [8] Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer A Phase 3 Randomized Clinical Trial
    Okamoto, Isamu
    Nokihara, Hiroshi
    Nomura, Shogo
    Niho, Seiji
    Sugawara, Shunichi
    Horinouchi, Hidehito
    Azuma, Koichi
    Yoneshima, Yasuto
    Murakami, Haruyasu
    Hosomi, Yukio
    Atagi, Shinji
    Ozaki, Tomohiro
    Horiike, Atsushi
    Fujita, Yuka
    Okamoto, Hiroaki
    Ando, Masahiko
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Nakagawa, Kazuhiko
    [J]. JAMA ONCOLOGY, 2020, 6 (05)
  • [9] EXPLORATORY SUBSET ANALYSIS IN AFRICAN AMERICANS FROM THE POINTBREAK STUDY (RANDOMIZED PHASE 3 PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED plus BEVACIZUMAB VERSUS PACLITAXEL plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB/IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
    Reynolds, Craig
    Patel, Jyoti D.
    Garon, Edward
    Olsen, Mark R.
    Bonomi, Philip
    Govindan, Ramaswamy
    Obasaju, Coleman
    Pennella, Eduardo J.
    Liu, Jingyi
    Guba, Susan C.
    Spigel, David
    Hermann, Robert C.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S562 - S562
  • [10] Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non-Small-Cell Lung Cancer of Nonsquamous Histology
    Zinner, Ralph G.
    Saxman, Scott B.
    Peng, Guangbin
    Monberg, Matthew J.
    Ortuzar, Waldo I.
    [J]. CLINICAL LUNG CANCER, 2010, 11 (05) : 352 - 357
12345